|Bid||0.0000 x 3000|
|Ask||0.0000 x 2200|
|Day's range||1.7400 - 1.8600|
|52-week range||1.5550 - 4.7110|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points. Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint?
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.